Brimelow Stresses Need For Better Patent System; Discusses Harmonisation 17/09/2009 by Kaitlin Mara for Intellectual Property Watch 1 Comment The way the patent system is currently structured rewards slowness and low quality, but the needed changes will have to include a new revenue model, a top European patent official said today.
New EU Communication On Increased IP Enforcement 14/09/2009 by William New, Intellectual Property Watch 4 Comments The European Commission Trade Directorate today adopted a “communication on enhancing the enforcement of intellectual property rights” within the European Union internal market that aims at greater coordination but stops short of new legislative measures.
‘Positive Noises’ On Resuming Talks On WIPO Audiovisual Performances Treaty 09/09/2009 by William New, Intellectual Property Watch Leave a Comment The World Intellectual Property Organization this week may have witnessed the beginnings of a resumption of high-level negotiations on an international treaty on the protection of audiovisual performances.
Early Drafts Show Disagreement On UN Framework For Climate Services 04/09/2009 by William New, Intellectual Property Watch Leave a Comment Senior officials from well over 100 nations at a five-day United Nations conference on Thursday issued a succinct declaration committing them to establish a global framework on the delivery of products and services related to climate change. But earlier negotiating versions of the declaration from the week obtained by Intellectual Property Watch show substantive disagreement and the removal of pages of draft text.
Punke Nominated As WTO Ambassador; Stoll To Succeed Doll As US Patent Commissioner 03/09/2009 by William New, Intellectual Property Watch Leave a Comment The Obama administration on Thursday announced several key changes related to intellectual property rights and trade.
Novartis Persists In Challenge To Indian Patent Law; India Rejects More AIDS Drugs Patents 02/09/2009 by Robinson Esalimba for Intellectual Property Watch 5 Comments Undeterred by two previous decisions by Indian authorities holding that under Indian Patent Law, its leukaemia drug – Gleevec is not patentable, Novartis now wants to take the fight to the Indian Supreme Court. Meanwhile, also this week, sources say Indian authorities rejected applications for patents on two HIV/AIDS drugs, opening the way for cheaper generic versions to be developed and marketed.
UN Climate Report Envisions Modified TRIPS As Governments Seek Progress 01/09/2009 by William New, Intellectual Property Watch 3 Comments Scientists and bureaucrats meeting this week on climate change and weather data are struggling to move global discussion past general declarations of recognition and commitment to address environmental change. One bump under the rug at the United Nations conference is rights over environmental technologies, and a new UN report released Tuesday calls for investment and a focus on flexibilities in and possible changes to intellectual property rights rules to help developing countries access information and technologies.
Informal UN Climate Talks Indicate Continued Divergence On IP Issues 28/08/2009 by Kaitlin Mara for Intellectual Property Watch 2 Comments With 15 scheduled negotiating days left before a meeting in Copenhagen meant to set the global sustainability agenda for the next several years, the head of the United Nations agency tasked with coordinating the global effort to fight climate change has issued an urgent call for more speed toward convergence on all parts of the upcoming climate change agreement, especially on IP-related text – lest the entire thing fall through.
EU, US Bristle As Drug Innovators Pay To Delay New Generics 25/08/2009 by Steven Seidenberg for Intellectual Property Watch Leave a Comment Authorities in the European Union and the United States have recently taken a tougher stance against reverse payments – patent settlements whereby, according to many competition experts, dominant drug companies buy off potential rivals.
Indian High Court Rejects Bayer Complaint For Patent Linkage 21/08/2009 by Monika Ermert for Intellectual Property Watch and Kaitlin Mara for Intellectual Property Watch 3 Comments Indian generics manufacturer Cipla can get marketing approval for its generic cancer treatment Soranib, the Delhi High Court ruled Tuesday, and the Indian drug regulatory authority does not have to check its patent status first. The court this week rejected a complaint by drug multinational Bayer against the Union of India, the Drug Controller General of India and generic drug producer Cipla. Bayer sought a court order requiring DCGI to consider the patent status of kidney cancer drug, sorafenib tosylate (sold under the brand name Nexavar), before granting marketing approval for a generic version of the drug. At issue was whether it is legitimate to link a potential violation of IP rights to processes regulating a drug’s entry onto the market that are generally based on drug quality, efficacy and safety.